6-month, open-label, randomized, multicenter, prospective, controlled study to evaluate the efficacy, safety and tolerability of Everolimus in de novo renal transplant recipients participating in the Eurotransplant senior program

Registry ID

EUCTR2008-005109-20

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Novartis Pharma GmbH

Start date

2009-06-09

Completion date

2013-03-21

Last update

2026-08-16

Conditions

• renal transplantation

Summary

The primary objective of this trial is to exploratively examine superiority of a treatment regimen with Certican with respect to the renal function at 6 months after renal transplantation (Tx) assessed by glomerular filtration rate (GFR) – Cockcroft-Gault method - as compared to the standard regimen in de novo senior renal transplant recipients

Locations

• , , Germany

View on source registry